We showed previously a direct arrhythmogenic effect of the intracoronary infusion of endothelin-1 (ET-1). We aimed to examine the electrophysiological effects of intracoronary bolus administration of ET-1 using monophasic action potential (MAP) recordings. Eight mongrel dogs received boli of ET-1 (1 and 2 nmol) into the left anterior descending coronary artery. These intracoronary ET-1 boli rapidly caused a marked decrease in coronary blood flow (1 nmol, 78p7 % ; 2 nmol, 89p7 %). Ischaemic changes of MAP morphology, a decrease in upstroke velocity (baseline, 1.78p0.2 V/s ; 1 nmol, 0.95p0.18 V/s ; 2 nmol, 0.45p0.21 V/s ; P 0.01) and a decrease in MAP duration at 90 % repolarization (MAPD 90 ) [1 nmol, from 191p3 to 176p5 ms (P 0.05) ; 2 nmol, from 212p4 to 180p8 ms (P 0.05)] occurred after ET-1 bolus administration. However, at 7-10 min after the 1 nmol bolus, a significant increase in MAPD 90 was observed (10 min, in the left ventricular anterior epicardial region : from 191p3 to 206p6 ms; P 0.05). The incidence of ventricular arrhythmias was as follows : after the 1 nmol ET-1 bolus : ventricular tachycardia, 3/8 animals ; ventricular fibrillation, 1/8 ; after the 2 nmol ET-1 bolus : ventricular tachycardia, 5/7 ; ventricular fibrillation, 5/7. MAP alternans was present in each animal (1 nmol, 18.2p5.8 % ; 2 nmol, 10.8p2.5 %). Thus electrophysiological and coronary blood flow changes indicate the predominance of an ischaemic arrhythmogenic effect of the bolus administration of ET-1 (shortening of action potential duration ; appearance of MAP alternans), whereas the observed delayed prolongation of MAPD 90 suggests a direct arrhythmogenic effect of ET-1. The expressed MAP alternans could have a pathogenic role in the onset of ventricular arrhythmias induced by an intracoronary bolus of ET-1.
INTRODUCTION
Endothelin-1 (ET-1), the best characterized isoform of a group of small endogenous peptides called the ETs, displays a potent and long-lasting coronary vasoconstrictory effect, and produces an increase in cardiac Correspondence : Dr Be! la Merkely (e-mail merkbel!hermes.sote.hu).
contractility via specific myocardial binding sites. The intracoronary bolus administration of ET-1 has been shown to induce severe ventricular tachyarrhythmias, associated with myocardial ischaemia [1] [2] [3] . We have demonstrated previously a direct arrhythmogenic effect of low-dose intracoronary infusion of ET-1 [4] [5] [6] . The development of multifocal ventricular tachycardias was based on action potential prolongation and the occurrence of early after-depolarizations (EADs). However, the electrophysiological effects of the intracoronary bolus administration of ET-1 have not been studied.
In the present study we aimed to investigate the electrophysiological and arrhythmogenic effects of highdose (1 and 2 nmol) intracoronary bolus administration of ET-1 using monophasic action potential (MAP) recordings.
MATERIALS AND METHODS
A total of eight mongrel dogs were anaesthetized with sodium pentobarbital (30 mg\kg, intravenous) and ventilated with humidified room air. Thoracotomy was carried out in the fifth intercostal space, and then the pericardial sac was opened and the left anterior descending artery was isolated. Mean arterial blood pressure was measured through a right femoral artery cannula, and coronary blood flow (CBF) was measured with an electromagnetic flowmeter placed on to the left anterior descending artery. Standard ECG leads were recorded throughout the study. Left ventricular apical endocardial (LV endo ) and right ventricular apical endocardial (RV endo ) MAPs were recorded through a fractally coated electrode (Alcath 4F ; Biotronik G.m.b.H.) [7] . A screw-in electrode (V-177 ; Biotronik) was used to record left ventricular anterior epicardial (LV epi ) MAP signs. The analogue MAP signals were recorded on a 12-channel direct chart recorder (Madaus Schwarzer CU 12) and the digitized signals were stored on a PC. QT time and MAP duration at 90 % repolarization (MAPD *! ) were determined at 300 ms cycle length, with stimulation applied for 10 ms (UHS 20 heart stimulator ; Biotronik). Only data from recordings with a stable resting potential were included in the data analysis. Upstroke velocity was defined as the quotient of the depolarization amplitude and the depolarization duration of the MAP curve.
After the registration of baseline haemodynamic and electrophysiological values, an intracoronary bolus of 1 nmol of ET-1 was administered into the left anterior descending artery. In the seven dogs that survived the 1 nmol bolus, a 2 nmol ET-1 bolus was given 25 min after the first bolus, following stabilization and the disappearance of ischaemic ECG and MAP changes.
Data are expressed as meanspS.E.M. Comparisons within the groups were analysed by ANOVA for repeated measurements. Student's paired t test was used to study changes in different variables following ET-1 administration. Significance was established at P 0.05.
RESULTS
Both the 1 nmol and 2 nmol ET-1 boli caused a rapid decrease in CBF [max. decrease in CBF before the onset of tachyarrhythmias : 1 nmol, 78p7% (P 0.001) ; 2 nmol, 89p7% (P 0.005)] (Figure 1 ). In parallel, significant ST changes on ECG lead II were observed [max. change in ST : 1 nmol, 0.15p0.04 mV (P 0.005) ; 2 nmol, 0.18p0.05 mV (P 0.005)]. The maximal decrease in CBF and the maximal ST changes were seen 0.5-3 min after ET-1 bolus administration with both the 1 and 2 nmol doses.
The 1 nmol ET-1 bolus led to ischaemic changes in MAP morphology in all cases. For LV epi MAP signals, a decrease in upstroke velocity, with a maximum effect 9-10 min after the ET-1 bolus (baseline, 1.78p0. nificantly in the LV epi and RV endo regions within 0.5-3 min of bolus administration compared with the steady state at 25 min (LV epi : 3 min, 212p4 ms ; 25 min, 180p 8 ms; P 0.01) (Figure 1 ), but not compared with the control period (0 min).
The 1 nmol ET-1 bolus induced non-sustained ventricular tachycardia 14-15 min after administration, leading to polymorphic ventricular tachycardia and ventricular fibrillation after 21 min, in one dog. The 2 nmol ET-1 bolus induced non-sustained ventricular tachycardia in four animals within 2-10 min of administration. Mono-and poly-morphic sustained ventricular tachycardias and ventricular fibrillation occurred in five animals in the 4-12 min following the 2 nmol ET-1 bolus.
EADs could be observed in the LV epi region following administration of 1 nmol of ET-1 in one animal, but no EADs were seen after the 2 nmol bolus of ET-1. Persistent MAP alternans, defined as the difference in duration of two consecutive MAPs over 20 beats, was a consistent finding in the LV epi region early after both doses of ET-1 in each animal (Figure 2 ). The magnitude of MAP alternans, expressed in terms of the difference in the duration of two consecutive MAPs at 90 % repolarization inside the LV epi zone, was 18.2p5.8 % and 10.8p2.5 % after 1 and 2 nmol of ET-1 respectively. MAP alternans was accompanied by T-wave alternans in the ECG (Figure 2 ).
DISCUSSION
Since its discovery [8] , several reports have been published on the arrhythmogenic effects of ET-1 [1] [2] [3] 9] . The first results referred to the secondary arrhythmogenic effect of ET-1 due to strong coronary vasoconstriction and ischaemia [1] [2] [3] 9] .
MAP recording is one of the most sensitive in vivo electrophysiological methods for the detection of local myocardial ischaemia [10, 11] . Changes in MAP duration in the ischaemic area are thought to occur in two ways [12] : the more usual shortened action potential duration of ischaemic cells, and an alternans of action potential in ischaemic cells. Various clinical and experimental data suggest a relationship between alternation of action potential duration of the ischaemic myocardium and ventricular arrhythmias [13] [14] [15] . Induction of short-term ischaemia in dogs showed that alternans of action potential recorded from the ischaemic centre zone preceded ventricular fibrillation in 95 % of cases [16] . The suggestion is that action potential duration alternans, causing inhomogeneities of ventricular repolarization in disparate myocardial regions, sets up the conditions for ventricular arrhythmias. Such differences in action potential duration could induce a regional conduction block due to differential refractoriness, or could result in a flow of injury current, both of which may facilitate ventricular arrhythmias. Ischaemic action potential duration alternans, reflecting cellular repolarization abnormalities, is probably the major cause of ischaemic T-wave alternans [17] . In one experimental study, severe conduction delay occurred concomitantly with episodes of alternans of action potential or ST segment elevation preceding ventricular arrhythmias, suggesting that re-entry is the mechanism of arrhythmia [18] . In another study that examined the role of ST alternans in the occurence of ventricular fibrillation after reperfusion in dogs, the magnitude of ST alternans increased progressively until ventricular fibrillation occurred. Activation of ventricular premature complexes resulted in conduction block and formed re-entry, leading to the conclusion that ST alternans related to ventricular fibrillation by facilitating the formation of a re-entrant circuit [19] .
In the present study, ET-1 caused a decrease in CBF immediately after bolus administration ; this was followed by severe ischaemic ECG and MAP changes, shortening of the MAP duration and a decrease in the upstroke velocity in the LV epi region. The observed biphasic effect of the administration of a 1 nmol bolus of ET-1 on LV epi MAPD *! could be the result of a marked epicardial ischaemic MAPD *! decrease, followed by an increase in MAPD *! due to a direct electrophysiological effect of ET-1. The continuous lengthening of MAP signals observed in the LV endo region following the 1 nmol ET-1 bolus could be the result of dominant direct electrophysiological effects of ET-1. However, severe ventricular tachyarrhythmias, based mainly on an ischaemic arrhythmogenic effect, were observed after the 2 nmol ET-1 bolus.
In our previous study, the appearance of significant ventricular arrhythmias, induced by 30-min intracoronary infusion of ET-1 (60 pmol\min), was observed without ischaemic MAP and ECG changes [5] . ET-1 infusion for 30 min did not lead to ischaemic MAP or ECG changes. The lengthening of MAP duration and expressed EAD formation were due to the direct arrhythmogenic effect of ET-1. The total dosage of the infusion was comparable with that applied as a bolus in the present study.
Expressed MAP alternans was present inside the ischaemic zone following the ET-1 bolus ; however, MAP alternans did not occur during intracoronary ET-1 infusion. MAP alternans was observed after the appearance of ischaemic electrophysiological signs, just before the onset of serious ventricular tachyarrhythmias. The appearance of T-wave alternans was well correlated with the occurence of MAP alternans, suggesting that T-wave alternans was due to changes in the MAP configuration.
In conclusion, electrophysiological (shortening of action potential duration ; appearance of MAP alternans) and CBF changes suggest the predominance of an ischaemic (indirect) arrhythmogenic effect of a bolus administration of ET-1, whereas the observed delayed prolongation of MAPD *! suggests a direct arrhythmogenic effect of ET-1. MAP alternans caused by ET-1 has been demonstrated for the first time in this model. This well expressed MAP alternans could have a pathogenic role in the onset of ventricular arrhythmias induced by an intracoronary bolus of ET-1. Theoretically, in pathophysiological conditions, both mechanisms of arrhythmia may play a role in the development of severe life-threatening ventricular tachyarrhythmias.
